Last week 25 generic drugs passed the consistency evaluation and seven became injections

Last week, NMPA issued two rounds of approval documents, and a total of 25 generic drugs passed the consistency evaluation, of which 9 were approved under the new registration classification, and 16 supplementary applications were reviewed.

The three products were first reviewed by Haisco, Hausen and Kelun; injections accounted for an eye-catching proportion, 70% of the reviewed products were injections (the part marked in blue in the table); 5 products were reviewed by the third.

Palonosetron Hydrochloride Injection

Palonosetron is a second-generation selective serotonin receptor antagonist.

The Insight database shows that there are currently 7 companies submitting supplementary applications for consistency evaluation of Palonosetron Hydrochloride Injection, 4 companies have submitted applications for listing on the new registration classification, and 1 company is in the BE trial stage.

"Palonosetron Hydrochloride Injection" Consistency Evaluation Details (Insight)

From the Insight database (http://db.

Decitabine for Injection

Decitabine is a treatment drug for myelodysplastic syndrome (MDS).

Details of the consistency evaluation of "Decitabine for Injection" (Insight)

From the Insight database (http://db.

Fat emulsion injection (C14～24)

The Insight database shows that there are currently 19 companies producing and selling fat emulsion injections (C14~24), but only Kelun submitted a supplementary application and became the first company to pass the evaluation.

"Fat emulsion injection (C14～24)" consistency evaluation details (Insight)

From the Insight database (http://db.